Why Biotech Titans Are Clashing Over Cholesterol

Why Biotech Titans Are Clashing Over Cholesterol


Amgen just won an important victory in its long patent war with Sanofi and Regeneron regarding the use of monoclonal antibodies to reduce cholesterol. are locked in a heated patent battle, and a judge's decision to halt sales of Sanofi's cholesterol-lowering drug, Praluent, which is co-marketed by Regeneron Pharmaceuticals Inc. , puts Amgen firmly in the driver's seat in what could be a multibillion-dollar market for next-generation cholesterol-lowering medicine.



from Biotech News